Ensysce Biosciences (ENSC) Competitors $0.59 -0.06 (-9.20%) (As of 11/21/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ENSC vs. ESLA, ICCC, LTRN, ACST, PMN, LIAN, ALTS, SRZN, KALA, and RNXTShould you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include Estrella Immunopharma (ESLA), ImmuCell (ICCC), Lantern Pharma (LTRN), Acasti Pharma (ACST), ProMIS Neurosciences (PMN), LianBio (LIAN), Janone (ALTS), Surrozen (SRZN), KALA BIO (KALA), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical products" industry. Ensysce Biosciences vs. Estrella Immunopharma ImmuCell Lantern Pharma Acasti Pharma ProMIS Neurosciences LianBio Janone Surrozen KALA BIO RenovoRx Estrella Immunopharma (NASDAQ:ESLA) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking. Which has better earnings & valuation, ESLA or ENSC? Estrella Immunopharma has higher earnings, but lower revenue than Ensysce Biosciences. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.48Ensysce Biosciences$2.23M3.68-$10.61M-$1.83-0.32 Which has more volatility and risk, ESLA or ENSC? Estrella Immunopharma has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Does the media prefer ESLA or ENSC? In the previous week, Estrella Immunopharma and Estrella Immunopharma both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ensysce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ESLA or ENSC more profitable? Estrella Immunopharma has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -179.26%. Estrella Immunopharma's return on equity of -195.77% beat Ensysce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -195.77% -157.28% Ensysce Biosciences -179.26%-292.81%-158.83% Does the MarketBeat Community believe in ESLA or ENSC? Ensysce Biosciences received 3 more outperform votes than Estrella Immunopharma when rated by MarketBeat users. CompanyUnderperformOutperformEstrella ImmunopharmaN/AN/AEnsysce BiosciencesOutperform Votes360.00% Underperform Votes240.00% Do institutionals and insiders hold more shares of ESLA or ENSC? 0.4% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 55.1% of Estrella Immunopharma shares are held by insiders. Comparatively, 7.9% of Ensysce Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryEstrella Immunopharma beats Ensysce Biosciences on 6 of the 11 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get Ensysce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENSC vs. The Competition Export to ExcelMetricEnsysce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.22M$6.52B$5.11B$8.84BDividend YieldN/A8.11%5.05%4.07%P/E Ratio-0.327.36108.8915.88Price / Sales3.68366.511,233.2287.15Price / CashN/A52.5939.9336.27Price / Book1.2610.176.946.36Net Income-$10.61M$153.36M$119.18M$226.00M7 Day Performance-6.81%-1.61%-1.36%-0.02%1 Month Performance187.57%-7.15%-3.27%1.95%1 Year Performance-31.12%31.68%32.40%27.80% Ensysce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENSCEnsysce Biosciences0.2193 of 5 stars$0.59-9.2%N/A-27.1%$8.22M$2.23M-0.3210Gap DownESLAEstrella Immunopharma0.6342 of 5 stars$0.91-2.2%N/A-33.5%$32.74MN/A-3.54N/AGap DownICCCImmuCell0.51 of 5 stars$3.66+1.7%N/A-22.1%$32.61M$17.47M-7.2075LTRNLantern Pharma1.0545 of 5 stars$2.95+0.3%N/A-27.0%$31.80MN/A0.0020ACSTAcasti Pharma2.3678 of 5 stars$3.37-0.9%$10.00+196.7%+59.0%$31.68MN/A-2.3432PMNProMIS Neurosciences1.1238 of 5 stars$0.96-4.0%N/A-30.8%$31.22M$10,000.00-9.556LIANLianBio1.1244 of 5 stars$0.29flat$3.50+1,115.5%-93.1%$31.12MN/A-0.36110ALTSJanone1.2299 of 5 stars$2.15-1.8%N/AN/A$30.81M$7.11M0.00170SRZNSurrozen1.4586 of 5 stars$9.30+4.5%N/A+25.6%$30.23M$12.50M0.0042Gap UpKALAKALA BIO4.1008 of 5 stars$6.55+1.9%$15.00+129.0%+7.8%$30.20M$3.89M-0.5330Gap DownRNXTRenovoRx2.6441 of 5 stars$1.25+5.0%$6.13+390.0%+98.7%$30MN/A-2.126News CoverageHigh Trading Volume Related Companies and Tools Related Companies ESLA Alternatives ICCC Alternatives LTRN Alternatives ACST Alternatives PMN Alternatives LIAN Alternatives ALTS Alternatives SRZN Alternatives KALA Alternatives RNXT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENSC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ensysce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
